LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today provided a business update […]
Other News
Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results
Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. […]
Tempus Launches First Cardiology Prospective Study for Its AI-Enabled Predictive Tests
In collaboration with iRhythm, Tempus is studying its predictive, AI-enabled algorithmic tests via a network of researchers to determine the impact of detecting patients at increased risk of developing cardiovascular disease CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of a multi-center study titled, […]
AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System. Building on acute data from the PASS PULL EV-ICD Study (n=18) completed in Q1-2022, the Sensing and Defibrillation with a Commercially Available ICD coupled with a Parasternal […]
Elucid Appoints Dr. Michael Lesh to Board of Directors
BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors. “We look forward to what Dr. Lesh will bring to the board with his extensive background […]
Endologix Reports Five-Year Data of the LEOPARD Trial at 2022 Vascular InterVentional Advances (VIVA) Conference
The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies […]
Cardior Appoints Axel-Sven Malkomes as Chief Financial Officer
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Axel-Sven Malkomes as Chief Financial Officer (CFO). Mr. Malkomes joins the executive leadership team to lead Cardior’s financial operations and planning, risk and compliance, investor relations and […]
LivaNova Reports Third-Quarter 2022 Results
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2022. Financial Summary and Highlights1 Revenue of $252.6 million for the quarter decreased 0.2 percent on a reported basis and increased 5.2 percent on a constant-currency basis, as compared […]
AtriCure Reports Third Quarter 2022 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results. “We are proud to share another quarter of strong commercial execution across our business, with excellent EnCompass […]
iRhythm® Technologies Comments on the Announcement of the Medicare Physician Fee Schedule Final Rule Released by the Centers for Medicare and Medicaid Services for Calendar Year 2023
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today commented on the recent announcement from the Centers for Medicare and Medicaid Services (“CMS”) that it has issued the Medicare Physician Fee […]



